Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > iCo Therapeutics Inc. does not say why stock is up

<< Previous

Bullboard Posts

Next >>

Post by Davidtepperss62on Apr 07, 2020 4:09pm

303 Views

Post# 30887946

iCo Therapeutics Inc. does not say why stock is up

An anonymous director reports

UNAWARE OF ANY MATERIAL CHANGE

At the request of IIROC, iCo Therapeutics Inc.has confirmed that management is unaware of any corporate development, news or undisclosed material changes to the company, or its operations, that would account for the recent increase in the company's share price and trading volume.

iCo Therapeutics Inc. to engage in its normal course of business and has no information to disclose.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario